UBS Starts Diplomat Pharmacy (DPLO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Mizuho Securities Cuts Price Target as Recent Sell-offs of Specialty Pharma Manufactures Negatively Effect Diplomat Pharmacy (DPLO)
October 21, 2015 6:43 AM EDTMizuho Securities maintained a Buy rating on Diplomat Pharmacy (NYSE: DPLO), and cut the price target to $44.00 (from $53.00), following recent sell-offs of specialty pharmacy manufactures. DPLO does not distribute any VRX or HZNP products. DPLO manages and distributes complex drugs for chronic conditions unlike... More
